There were no clinically relevant modifications as compared to 2011 except for new info and new recommendations regarding the treatment with bisphosphonates and denosumab (see segment ‘Bisphosphonates and RANKL Antibody Denosumab’). element is present or not. The prerequisites for a qualified axillary dissection ended up also outlined far more https://juliann530irz7.aboutyoublog.com/profile